Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
Moist wound dressing for chronic wound treatment now available in Germany
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.
This product will be launched through Granules Consumer Health (GCH) division
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Subscribe To Our Newsletter & Stay Updated
